Pacritinib
CAS 937272-79-2Small Molecule
Overview
Pacritinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL2035187).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Pacritinib expires 25 Mar 2030 and exclusivity 28 Feb 2029. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- (16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
- Canonical SMILES
- C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2
- InChIKey
- HWXVIOGONBBTBY-ONEGZZNKSA-N
Verified Supplier Partner
Do you supply Pacritinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.